Page 2 of 14 – SEC Filing CUSIP No. 05070R104 13G Page 2 of 11
1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Mgmt, L.P. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) o (b) ý 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 514,424 (1) 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 514,424 (1) 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 514,424 (1) 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* o 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.45% 12. TYPE OF REPORTING PERSON* PN
__________________ (1) Comprised of Common Stock held by Deerfield Special Situations Fund, L.P. of which Deerfield Mgmt, L.P. is the general partner. Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
| CUSIP No. | 05070R104 | 13G | Page 2 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Mgmt, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 514,424 (1) | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 514,424 (1) | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 514,424 (1) | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.45% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
__________________
(1) Comprised of Common Stock held by Deerfield Special Situations Fund, L.P. of which Deerfield Mgmt, L.P. is the general partner.
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.